Peptides in the Cayman Islands: a guide for Caymanian physicians

Who this guide is for

This guide is for physicians practicing in the Cayman Islands who want the data before they form an opinion. Patients now arrive asking about semaglutide, tirzepatide and the "peptides" they see online, and the islands carry a heavy metabolic burden: the STEPS 2023 National Health Survey measured 69.6% of adults as overweight or obese and 32.7% as obese, with obesity at 41.1% among women and 24.6% among men⁶. Below we set out what the evidence shows, what Cayman law says as written today, and what regulators and police have done recently.

Peptides are an established drug class

Peptides are not a fad. More than 80 peptide drugs have reached the market, for diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain¹. The GLP-1 era rests on large randomized trials. In SELECT, 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes were randomized to semaglutide or placebo; the primary cardiovascular endpoint occurred in 6.5% versus 8.0% (hazard ratio 0.80)². In STEP 1, 1,961 adults lost a mean 14.9% of body weight with semaglutide versus 2.4% with placebo³. In SURMOUNT-1, 2,539 adults lost 15.0%, 19.5% and 20.9% at the three tirzepatide doses versus 3.1% with placebo at 72 weeks⁴.

On 1 December 2025 the World Health Organization issued its first guideline on these drugs, with a conditional recommendation that GLP-1 therapies may be used by adults, excluding pregnant women, for the long-term treatment of obesity. WHO also warned that the therapies are projected to reach fewer than 10% of those who could benefit by 2030⁵.

What Cayman law actually says

Three texts matter: the Health Practice Act (2026 Revision), published as Supplement No. 4 to Legislation Gazette No. 7 of 5 February 2026 and revised as at 31 December 2025⁷; the Pharmacy Act, 1979, which still governs medicines; and the Pharmacy Act, 2024, which Parliament passed but which the official legislation website lists as not in force¹⁰.

• Who regulates. The Department of Health Regulatory Services publishes the registers of the Medical and Dental Council, the Nursing and Midwifery Council, the Pharmacy Council and the Council for Professions Allied with Medicine, plus the list of registered health care facilities⁸. Under section 5 of the Health Practice Act, the Health Practice Commission issues the certificate needed to operate a health care facility⁷.
• Facilities. Operating a health care facility without a certificate is an offence carrying a fine of fifty thousand dollars and a further ten thousand dollars for every day of operation (section 15(1)). Operators must ensure their practitioners have approved malpractice insurance or indemnity cover, with a twenty-five thousand dollar fine for failing to do so (section 15(2) and (3)). Clinical services at every facility must be managed by a registered practitioner on the principal list of a Council (section 8)⁷.
• Titles. Section 38(1) makes it an offence to wilfully and falsely pretend to be, or use the title of, a physician, doctor of medicine, surgeon, pharmacist, nurse or any title implying registration. The fine is ten thousand dollars, plus two thousand dollars for every day the offence continues after conviction (section 38(4))⁷.
• Discipline. Each Council publishes a code of practice that registered practitioners must follow (section 35). For negligence, dishonesty, a criminal conviction or breach of the code, a Council may censure, impose conditions, suspend a licence for up to two years or strike the practitioner off (section 36)⁷.
• Clinical trials. A facility manager may not permit clinical trials without the prior written consent of the Commission; breach carries a ten thousand dollar fine (section 9)⁷.
• Medicines today. The 1979 Act still applies. In 2021 the Auditor General wrote that "The Pharmacy Act, which dates back to 1979, is not in line with current good practice and creates risks for the control and regulation of drugs that are able to be brought into the Cayman Islands"¹².
• The Pharmacy Act, 2024. Its second reading was moved on 23 July 2024 by the Minister for Health and Wellness, Sabrina Turner¹¹. In the Bill as published, an "approved medicine" is one approved in a country prescribed by regulations, approved by the Pharmacy Council, or covered by an exceptional or emergency use authorization; importing, selling by wholesale, dispensing, prescribing, administering or manufacturing a non-approved medicine carries a fine of twenty thousand dollars, five years in prison, or both (clause 15); retail supply is limited to pharmacists in certified pharmacies or dispensing-licence holders (clause 16); and internet and mail-order pharmacies with no physical premises are banned (clause 22)⁹. None of this applies until the Act is brought into force¹⁰.

In April 2026 Parliament also passed the Health Practice (Amendment) Bill, 2026, which lets Cabinet set overarching standards for every registered practitioner, covering areas such as prescribing and handling of medicines and clinical trials and research. Where a Cabinet standard conflicts with a Council code, "the Cabinet's standards will prevail to the extent of that inconsistency"¹³.

Recent cases and regulatory moves in the Cayman Islands

• Man charged with impersonating a doctor (June 2026). The Royal Cayman Islands Police Service charged a 66-year-old man with impersonating a doctor or licentiate of medicine and with buying or attempting to buy controlled drugs. Police said an investigation that began in December 2025 followed reports that an employee of a local medical services company had repeatedly bought prescription medication, including controlled drugs, while falsely presenting himself as a licensed doctor¹⁵.
• Clinical-trial guidance (January 2026). The Health Practice Commission published standards for appraising trial applications. It states that the islands lack an established research oversight infrastructure, that phase 1 trials are not foreseeable, and that participants must not be charged for taking part¹⁴.
• Cabinet standards (April 2026). The Health Practice (Amendment) Bill, 2026 passed Parliament, the first formal route to legally binding standards across all professions¹³.
• The unfinished pharmacy reform. More than two years after the vote, the Pharmacy Act, 2024 remains on the not-in-force list¹⁰¹¹.

The evidence map

Not everything sold as a "peptide" sits at the same level of evidence. GLP-1 receptor agonists have phase 3 trials with hard cardiovascular endpoints²³⁴. At the other end, a systematic review of BPC-157 included 36 studies, 35 of them preclinical and one clinical: in a retrospective series, 7 of 12 patients with chronic knee pain reported relief for more than six months, and no clinical safety data were found¹⁸. In between sits the regulatory debate: at its 23 and 24 July 2026 meeting, the US FDA's Pharmacy Compounding Advisory Committee voted in favor of six of seven peptides reviewed (BPC-157, KPV, TB-500, MOTS-c, epitalon and semax); emideltide failed²⁰.

How safe are they?

Approved peptides have well-characterized safety profiles. In SELECT, 16.6% of patients on semaglutide and 8.2% on placebo stopped treatment for adverse events²; in SURMOUNT-1, adverse events led to discontinuation in 4.3%, 7.1% and 6.2% across tirzepatide doses versus 2.6% on placebo⁴. In March 2026 the Pan American Health Organization said several countries had reported adverse events linked to GLP-1 misuse: mostly temporary gastrointestinal effects, and less commonly acute pancreatitis, gallbladder disease and intestinal obstruction. It warned that sales through the internet and social media can involve falsified, unauthorized or substandard products¹⁶. In April 2025 the FDA warned about counterfeit Ozempic (semaglutide) found in the US drug supply chain, lot PAR0362¹⁷.

For research peptides, the main gap is the absence of human data rather than a proven signal of harm¹⁸. Serious documented events are rare: at the 2025 RAADfest festival in Las Vegas, two women needed breathing tubes after peptide injections and later recovered; the Nevada pharmacy board could not obtain the product to test it and fined those involved for licensing violations¹⁹.

What it means for practice in the Cayman Islands

Patients will bring these questions, and sometimes these products, to the consulting room. The practical anchors are already in the law. Practitioner and facility lists are public, so registration can be checked⁸. Any clinical study in a facility needs the Commission's written consent⁷, and the Commission's standards expect prior phase 2/3 evidence of benefit and tolerability, written consent, insurance cover and reporting of serious events within 24 hours¹⁴. PAHO asks prescribers to report adverse events to national pharmacovigilance and to stay within approved indications¹⁶. Until the Pharmacy Act, 2024 is brought into force, the 1979 Act is the medicines law in the Cayman Islands¹⁰¹². The physician who knows both the evidence and the law becomes the patient's reference; if patients do not find that in the clinic, they will look for it online.